Journal of Crohn's & colitis最新文献

{"title":"Adequacy of disclosures in oral presentations at the 20th Congress of European Crohn's and Colitis Organisation.","authors":"Ethan X Tan, Ziheng Calvin Xu, Robert D Little","doi":"10.1093/ecco-jcc/jjaf121","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf121","url":null,"abstract":"","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tofacitinib Versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison.","authors":"Beatriz Gros, Nathan Constantine-Cooke, Jake Kennedy, Alexander T Elford, Claire O'Hare, Colin Noble, Gareth-Rhys Jones, Ian D Arnott, Charlie W Lees, Nikolas Plevris","doi":"10.1093/ecco-jcc/jjae188","DOIUrl":"10.1093/ecco-jcc/jjae188","url":null,"abstract":"<p><strong>Background and aims: </strong>Over the last decade, treatment options for moderate-to-severe ulcerative colitis (UC) have expanded. However, comparative studies between these agents are limited, especially among biologic-naive patients. We aimed to compare the persistence, effectiveness, and safety of tofacitinib and vedolizumab as the first advanced treatment for patients with UC.</p><p><strong>Methods: </strong>Patients who received either tofacitinib or vedolizumab as their first advanced therapy for UC in NHS Lothian were included. We used inverse probability of treatment weighting. The probability of treatment assignment was calculated via logistic regression using age, sex, UC duration, Montreal extent, C-reactive protein, concomitant corticosteroids, and partial Mayo score at drug commencement.</p><p><strong>Results: </strong>We included n = 158 patients, of whom n = 81 (51.3%) received vedolizumab and n = 77 (48.7%) tofacitinib. Median follow-up for vedolizumab patients was 3.1 years (interquartile range [IQR] 1.6-4.8) and for tofacitinib patients 1.5 years (IQR 0.3-2.3). The cohort was 59.5% male with a median age of 41.1 years (IQR 31.5-51.8). At 2 years, vedolizumab persistence was superior to tofacitinib (p = 0.005). At Weeks 12 and 52, clinical, biochemical, and fecal biomarker steroid-free remission were comparable between groups. Primary nonresponse and secondary loss of response were 9.9% and 17.3% for vedolizumab and 23.4% and 13% for tofacitinib, respectively. The frequency of adverse events was comparable (11 [13.6%] vedolizumab vs 19 [24.7%] tofacitinib, p = 0.629).</p><p><strong>Conclusions: </strong>We found that the persistence and tolerability of vedolizumab were superior to tofacitinib in bio-naive UC, although the rates of clinical and biomarker remission were comparable. These data may help inform the positioning of advanced therapy.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endo-Histo foundational fusion model: a novel artificial intelligence for assessing histologic remission and response to therapy in ulcerative colitis clinical trial.","authors":"Marietta Iacucci, Giovanni Santacroce, Pablo Meseguer, Alejandro Diéguez, Rocio Del Amor, Bisi Bode Kolawole, Ujwala Chaudhari, Irene Zammarchi, Brian Hayes, Rory Crotty, Davide Zardo, Yasuharu Maeda, Miguel Puga-Tejada, Ilaria Ditonno, Valentina Vadori, Louise Burke, Ferdinando D'Amico, Subrata Ghosh, Enrico Grisan, Valery Naranjo","doi":"10.1093/ecco-jcc/jjaf108","DOIUrl":"10.1093/ecco-jcc/jjaf108","url":null,"abstract":"<p><strong>Background and aims: </strong>Artificial intelligence (AI)-enabled endoscopy and histology offer accurate, objective, and rapid assessment of disease activity in ulcerative colitis (UC). Emerging multi-source AI models may enhance standardized disease evaluation and outcome prediction. This investigation aimed to develop a novel AI model fusing endoscopic and histologic features to improve the assessment of disease remission and response to therapy in UC clinical trials.</p><p><strong>Methods: </strong>A novel multimodal AI model was developed that fuses endoscopic videos and histologic whole-slide images from a Phase 2 clinical trial of Mirikizumab in UC (NCT02589665). Informative endoscopic frames were predicted using convolutional neural networks and processed with BioMedCLIP, while histologic features were extracted using the CONCH foundational model. Multimodal features were then integrated via multi-head self-attention to generate a patient-level assessment. Model performance for assessing histologic remission (HR) and treatment response at weeks 12 and 52, based on histologic endpoints, was evaluated by cross-validation.</p><p><strong>Results: </strong>The fusion model outperformed single-modality assessments for HR, achieving a sensitivity of 89.72% (95% CI, 82.35-94.76), specificity of 89.67% (95% CI, 84.34-93.67), and accuracy of 89.69% (95% CI, 85.61-92.94). It showed a sensitivity of 97.96% (95% CI, 89.15-99.95), specificity of 86.84% (95% CI, 71.91-95.59), and accuracy of 93.10% (95% CI, 85.59-97.43) for assessing HR at week 52. Substantial agreement was observed between the AI-fusion model and central readout.</p><p><strong>Conclusion: </strong>This novel tool significantly advances precision medicine in clinical trials by potentially standardizing central readouts and enabling automated disease assessment.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenome-wide association study of monogenic inflammatory bowel disease genes in diverse biobanks identifies population-specific and shared Goldilocks alleles: implications for Precision Medicine.","authors":"Michelle M Bao, Meltem Ece Kars, David Zhang, Kyle Gettler, Daniel Rader, Scott Snapper, Yuval Itan, Judy H Cho","doi":"10.1093/ecco-jcc/jjaf098","DOIUrl":"10.1093/ecco-jcc/jjaf098","url":null,"abstract":"<p><strong>Background and aims: </strong>Monogenic forms of inflammatory bowel disease (IBD) are driven by variants in genes critical to pathways in intestinal homeostasis and immunity. We investigated gene- and variant-level effects of these genes with IBD and phenome-wide association, leveraging large-scale whole exome sequencing data across 4 diverse cohorts: BioMe Biobank (Regeneron and Sema4), Penn Med Biobank, and UK Biobank.</p><p><strong>Methods: </strong>Predicted loss- and gain-of function variants were extracted from 102 monogenic genes. Gene- and variant-level association tests for binary traits were performed across 4 cohorts grouped based on genetic similarity in European, African, and Admixed American populations.</p><p><strong>Results: </strong>From 11 546 variants extracted, over two-thirds were predicted as loss-of-function (LOF), with 93% classified as ultra-rare and 1172 Goldilocks variants (not ultra-rare) enriched at least 10-fold in African populations. Gene-level IBD association testing demonstrated numerous replicated associations in European cohorts, reflecting well-powered independent cohorts. Twenty monogenic genes overlap with genome-wide IBD loci, fifteen of which displayed gene-level association trends. Heterozygous carriage of African-predominant LOF alleles in NPC1 (intracellular cholesterol transport) and ADA/ADA2 (purine metabolism), were associated with IBD. These variants also showed replicated associations with phenotypes related to cardiac conduction, infection, and lipid metabolism.</p><p><strong>Conclusions: </strong>We define overlap between monogenic and genome-wide IBD loci and reveal population-specific allelic heterogeneity of IBD risk genes. We uncover novel phenotype associations suggesting pleiotropic effects of monogenic IBD genes. African-predominant variants revealed allelic associations absent in European cohorts, and of potential clinical significance, underscoring the importance of increasing diversity in genetic studies.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":"19 7","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ECCO Topical Review on Pouch Disorders.","authors":"Maia Kayal, Gabriele Bislenghi, Michel Adamina, Zaid S Ardalan, Nicolas Avellaneda, Anthony de Buck van Overstraeten, Marjolijn Duijvestein, Maria Manuela Estevinho, Federica Furfaro, Ailsa L Hart, Stefan Holubar, Triana Lobaton, Jacob Ollech, Stephan R Vavricka, MarC Ferrante","doi":"10.1093/ecco-jcc/jjaf103","DOIUrl":"10.1093/ecco-jcc/jjaf103","url":null,"abstract":"<p><strong>Background: </strong>Pouch disorders are common and may present with symptoms of increased stool frequency, urgency, incontinence, pelvic cramping, obstructed defecation, and perianal drainage, which can result in poor sleep, fatigue, and disability. This topical review aims to offer expert consensus practice recommendations for the diagnosis and management of the most common inflammatory, functional, structural, and neoplastic J-pouch disorders.</p><p><strong>Methods: </strong>A multidisciplinary panel of gastroenterologists and colorectal surgeons performed a systematic review of the relevant literature on pouch disorders and developed current practice positions.</p><p><strong>Results: </strong>Seventeen current practice positions were developed on the diagnosis and management of inflammatory, functional, structural, and neoplastic pouch disorders.</p><p><strong>Conclusions: </strong>A multidisciplinary approach is essential for the diagnosis and management of pouch disorders.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between food diversity in the infant period and the risk of inflammatory bowel disease: a nationwide cohort study in South Korea.","authors":"Kyung A Kim, Junhyun Kwon, Woo-Jeong Shon, Joo Sung Kim, Byeong Gwan Kim, Jong Pil Im, Hyun Jung Lee, Hyunsun Park, Seong-Joon Koh","doi":"10.1093/ecco-jcc/jjaf101","DOIUrl":"10.1093/ecco-jcc/jjaf101","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence suggests that diet plays a significant role in the development of inflammatory bowel diseases. This study aimed to assess the association between early-life food diversity and the incidence of inflammatory bowel diseases from a nationwide retrospective cohort study in South Korea.</p><p><strong>Methods: </strong>This study incorporated 1 242 295 South Korean infants who participated in the National Health Insurance Service. Food diversity was categorized as \"high\" or \"low\" based on vegetables, fruits, grains, meats, fish, and eggs consumed during weaning. The association between food diversity and inflammatory bowel disease incidence was examined and subgroup analysis was conducted according to food diversity groups. The Cox proportional hazards model was used to estimate the risk of inflammatory bowel disease, with hazard ratios adjusted for demographic factors. Propensity score matching was employed for evaluating the general characteristics of the study population.</p><p><strong>Results: </strong>Among the infants evaluated, 71.3% of those who developed ulcerative colitis and 66.0% of those who developed Crohn's disease did not consume high-diversity food. Individually, food diversity, solid food intake frequency, antibiotic usage, and breastfeeding status were not significantly associated with inflammatory bowel disease incidence. However, the combination of high food diversity and frequent solid food intake (≥3 times/day) was associated with a lower risk of ulcerative colitis by 48% (adjusted hazard ratio: 0.52, CI 0.28-0.98, P = .0426).</p><p><strong>Conclusions: </strong>Food diversity, combined with the frequency of solid food intake, during infancy is associated with the incidence of ulcerative colitis. Promoting a diverse diet during infancy may be important in preventing the development of IBD.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The long-term disease course of microscopic colitis: a European prospective incident cohort study.","authors":"Bas P M Verhaegh, Andreas Münch, Danila Guagnozzi, Signe Wildt, Wojciech Cebula, Natalia Pedersen, Vytautas Kiudelis, Alfredo J Lucendo, Ivan Lyutakov, Gian-Eugenio Tontini, Flavia Pigò, Evangelos Russo, Henrik Hjortswang, Lars K Munck","doi":"10.1093/ecco-jcc/jjaf110","DOIUrl":"10.1093/ecco-jcc/jjaf110","url":null,"abstract":"<p><strong>Background and aims: </strong>The disease course of microscopic colitis is largely unknown and current knowledge is based on retrospective data. The aim of the PRO-MC Collaboration is to prospectively describe the long-term disease course and prognostic factors.</p><p><strong>Methods: </strong>Incident patients of microscopic colitis were included in a prospective, European, multicenter, web-based registry. Data on patient characteristics, symptoms, treatment, and quality of life were systematically registered at baseline and during fixed follow-up intervals. Four disease course phenotypes were defined.</p><p><strong>Results: </strong>Of 422 registered incident patients, 220 had a complete 5-year follow-up. After 5 years, 6% had a quiescent disease course, 54% achieved remission after treatment, 33% had a relapsing disease course, and 7% a chronic active disease course. Patients with a relapsing or chronic active disease course had a more impaired quality of life and were more often in need for long-term budesonide treatment. The disease course in the first year after diagnosis was the only predictor of the disease course.</p><p><strong>Conclusions: </strong>Microscopic colitis is a chronic condition with relapsing or continuous disease course in nearly half of the patients during the first 5 years after diagnosis. The disease course in the first year predicts the long-term disease course.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of complete vs partial endoscopic healing on long-term outcomes in Crohn's disease: a prospective multicenter study.","authors":"Clara Yzet, Franck Brazier, Elise Derval, Pierre Vanelslander, Valérie Dejour, Dumitrita Pricope, Momar Diouf, Mathurin Fumery","doi":"10.1093/ecco-jcc/jjaf104","DOIUrl":"10.1093/ecco-jcc/jjaf104","url":null,"abstract":"<p><strong>Introduction: </strong>The STRIDE II guidelines recognize endoscopic healing (EH), defined by an SES-CD score ≤ 2, as one of the main therapeutic targets in Crohn's disease (CD). Nevertheless, complete EH could further reduce the risk of long-term complications in CD. We aimed to assess the risk of long-term complications in CD according to the degree of EH achieved.</p><p><strong>Method: </strong>We conducted a prospective multicenter study including all patients with EH assessment (2019-2022) in 3 centers and compared the outcomes of patients with complete EH (CDEIS = 0) vs partial EH (CDEIS > 0 but < 4). The primary endpoint was therapeutic failure (need for drug intensification and/or corticosteroid initiation and/or CD-related hospitalization and/or intestinal resection and/or development of a luminal stricture/fistula and/or perianal CD).</p><p><strong>Results: </strong>In total, 128 patients were included. Patients had been on treatment for a median of 12 months (8.3-24.3) before colonoscopy. After a median follow-up of 22 months (interquartile range, 19-23), 40 (31%) patients experienced therapeutic failure. The risk of therapeutic failure was significantly higher among patients with partial EH (25% vs 43%, P = .036). The risk of CD-related hospitalization was significantly higher for patients with partial EH (2.5% vs 17%, P = .005; hazard ratio = 6.89, Interval confidence 95% (IC95%) = [1.46-32.4], P = .015). The risk of intestinal resection, steroid initiation, and drug intensification among patients with complete and partial EH, were 0% vs 4.3% (P = .13), 2.5% vs 11% (P = .1); and 22% vs 36% (P = .088), respectively.</p><p><strong>Conclusion: </strong>Although higher-powered studies are needed to confirm these findings, current results suggest that complete EH may be associated with more favorable long-term outcomes than partial EH in patients with CD.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label study.","authors":"Xavier Roblin, Sophie Vieujean, Stéphane Nancey, Xavier Hebuterne, Nadia Arab-Hocine, Guillaume Savoye, Stéphanie Viennot, Guillaume Bouguen, Mathurin Fumery, Gerard Duru, Elisabeth Botelho-Nevers, Anne-Emmanuelle Berger, Bernard Tardy, Nicolas Mathieu, Mathilde Barrau, Laurent Peyrin-Biroulet, Stephane Paul","doi":"10.1093/ecco-jcc/jjaf115","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf115","url":null,"abstract":"<p><strong>Background and aims: </strong>Pneumococcal vaccination is essential for patients with inflammatory bowel diseases (IBD), but its efficacy is reduced in those on antitumor necrosis factor (TNF) or immunosuppressive therapy. This study compared immune responses to standard versus intensified pneumococcal vaccination strategies in IBD patients receiving anti-TNF (±immunosuppressors) or vedolizumab.</p><p><strong>Methods: </strong>In a prospective, multicenter, randomized open-label study across 7 French university hospitals, IBD patients in clinical remission on biologic therapy (anti-TNF ± immunosuppressors, or vedolizumab) were randomized 1:1 to an intensified (PCV13/PCV13/PPSV23) or standard (PCV13/PPSV23) regimen. Vaccine response (ELISA and opsonophagocytic assays [OPA]), side effects, and disease activity were monitored over 36 months. The primary endpoint was vaccine response at month 5 (M5), defined as antibody titers >1 µg/mL for at least 9 of 13 serotypes in ELISA.</p><p><strong>Results: </strong>One hundred and four patients (median age, 43 years; 60.6% male; 68.3% Crohn's disease) were randomized to the standard (n = 51) or intensified (n = 53) regimen. At M5, the vaccine response was significantly higher in the intensified group compared to the standard group, as measured by ELISA (53.2% vs. 27.1%; relative risk [RR[ = 1.96; 95% CI, 1.15-3.36; P = .009) and OPA (90.9% vs. 62.5%; P = .007). OPA responses remained higher in the intensified group at M12, M18, and M36. Reduced responses were associated with anti-TNF therapy, combination therapy, and Crohn's disease. Both regimens were well tolerated, with no differences in safety profiles or IBD relapse rates.</p><p><strong>Conclusions: </strong>Intensified vaccination significantly enhances and sustains immune response over 36 months, particularly benefiting patients with CD on anti-TNF therapy.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":"19 7","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-guided strategies in ulcerative colitis: early prediction and targeting.","authors":"Mariangela Allocca, Emma Calabrese","doi":"10.1093/ecco-jcc/jjaf113","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf113","url":null,"abstract":"","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":"19 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}